April 3, 2018 / 1:13 PM / 5 months ago

BRIEF-Pfizer and Allogene enter into agreement for Pfizer's CAR T cell therapy

April 3 (Reuters) - Pfizer Inc:

* SAYS CO AND ALLOGENE THERAPEUTICS ENTER INTO ASSET CONTRIBUTION AGREEMENT FOR PFIZER’S ALLOGENEIC CAR T IMMUNO-­ONCOLOGY PORTFOLIO

* SAYS AGREEMENT AIMS TO ACCELERATE THE DEVELOPMENT OF PFIZER’S CAR T CELL THERAPY

* SAYS ALLOGENE WILL RECEIVE RIGHTS FROM CO TO 16 PRE-CLINICAL CAR T ASSETS LICENSED FROM CELLECTIS AND SERVIER

* SAYS ALLOGENE WILL RECEIVE RIGHTS TO ONE CLINICAL ASSET FROM SERVIER CALLED UCART19

* SAYS CO WILL HOLD 25 PERCENT STAKE IN ALLOGENE THERAPEUTICS; CO WILL BE REPRESENTED ON ALLOGENE’S BOARD Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below